Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating income | -$19.4M | -$26.1M | -$62.3M | -$123M |
| Net income | -$24.5M | -$99.9M | -$55.1M | -$117M |
| EPS (diluted) | $44.30 | $151.22 | $1.46 | $2.29 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$17.6M | -$24.7M | -$48.3M | -$99.2M |
| Capital expenditures | $153K | $318K | $925K | $1.49M |
| Free cash flow | -$17.7M | -$25.1M | -$49.2M | -$101M |
| Dividends paid | — | $0.00 | — | — |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $20.4M | $81.5M | $173M | $50.2M |
| Total assets | $23.9M | $87.0M | $311M | $221M |
| Total liabilities | $47.4M | $14.5M | $38.6M | $53.8M |
| Shareholders' equity | -$76.6M | $72.5M | $273M | $168M |
| Retained earnings | -$99.7M | -$200M | -$255M | -$372M |
| Shares (wtd avg diluted) | 655K | 693K | 37.8M | 51.1M |
Every figure is extracted from enGene Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.